Previous 10 | Next 10 |
MORRISVILLE, N.C., July 12, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2021 financial results on Monday, August 9, 2021, prior to its earnings call at 8:00 a.m. ET. ...
I will outline the history of drug development. Information for the Abcam business model will be outlined for my readers. As a secondary model for my readers, I will cite Syneos Health, Inc. For further details see: Abcam: A Promising Business Model In The Drug Industry ...
Syneos Health Inc. (NASDAQ:SYNH) traded at a new 52-week high today of $91.48. This new high was reached on below average trading volume as 121,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares. Based on a current price of $90.99, Syneos Health ...
Syneos Health Inc. (NASDAQ:SYNH) traded at a new 52-week high today of $90.17. This new high was reached on below average trading volume as 121,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares. Syneos Health Inc. share prices have moved between...
MORRISVILLE, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today expanded its Decentralized Clinical Trial capabilities to include a dedicated Decentralized Clinical Trials Site Advocacy Gr...
MORRISVILLE, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of David S. Wilkes, M.D., to the Company’s Board of Directors. “We are thrille...
The following slide deck was published by Syneos Health, Inc. in conjunction with this event. For further details see: Syneos Health (SYNH) Presents At Jefferies Virtual Healthcare Conference - Slideshow
I will share an update on the last two years of progress. An update on future milestones will be outlined. I will give investors a rudimentary outline for near-term revenues expected for Idorsia. For further details see: Idorsia: Putting The Capstone On A Foundationally ...
MORRISVILLE, N.C., June 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today launched its Patient Voice Consortium. The Consortium is a cross-functional hub designed to share expertise, resources and r...
Koss (KOSS) -14%.C3.ai (AI) -11% on FQ4 earnings release.Stealth BioTherapeutics (MITO) -11%.Express (EXPR) -11% on Q1 earnings releaseFireEye (FEYE) -10% after spins out FireEye Products business to Symphony for $1.2B.Bed Bath & Beyond (BBBY) -10%.PetMed Exp...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...